Q-omics provides the consensus-scored FOXN3-AS2 profile across patient tissues and cancer cell-line models. FOXN3-AS2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, FOXN3-AS2 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, FOXN3-AS2 RNA expression shows 9,097 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UCS, KIRC, and HNSC as cancer lineages where FOXN3-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXN3-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXN3-AS2 survival associations across molecular data types. FOXN3-AS2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXN3-AS2 RNA expression–survival associations across cancer types. High FOXN3-AS2 expression shows unfavorable associations in UCS, HNSC and THCA, but favorable associations in BLCA, SKCM and CESC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UCS as the clearest survival context for FOXN3-AS2 RNA expression.
This table summarizes FOXN3-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FOXN3-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXN3-AS2 shows lower tumor expression in LUAD, COAD and LUSC and higher tumor expression in KIRC, KICH and LIHC. The KIRC box plot shows higher FOXN3-AS2 RNA expression in tumor versus normal tissue (log2 FC = +0.014, t-test p < 0.001).
This table shows molecular features associated with FOXN3-AS2 in patient tissues and cancer cell lines. In patient samples, FOXN3-AS2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXN3-AS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
